AMIX Data on Pancreatic Cancer Pain Accepted for DDW 2026 Presentation

Autonomix Medical, Inc. announced that its long-term data, titled "Pain Mitigation in Pancreatic Adenocarcinoma: A Long-Term Analysis of Denervation via Transvascular RF Energy-Based Ablation," has been accepted for presentation at Digestive Disease Week 2026 (DDW 2026), taking place from May 2–5, 2026. The data highlights long-term outcomes associated with the company's transvascular radiofrequency (RF) energy-based ablation approach, which aims to disrupt nerve signaling pathways responsible for severe pain in pancreatic cancer patients. This acceptance at a preeminent conference validates Autonomix's strategy and findings.